3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer
Recruitment status was: Recruiting
|Prostate Cancer||Procedure: 3-Tesla magnetic resonance imaging Procedure: diffusion-weighted magnetic resonance imaging Procedure: dynamic contrast-enhanced magnetic resonance imaging Procedure: magnetic resonance spectroscopic imaging|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Imaging of the Prostate Gland Using High Field Strength 3T MRI|
- Diagnostic imaging quality of the prostate at 3T high field imaging without an endorectal coil [ Time Frame: Up to 6 years ]
|Study Start Date:||September 2007|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Experimental: Diagnostic (3T MRI)
Patients undergo 3T MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.
Procedure: 3-Tesla magnetic resonance imaging
Undergo 3T MRI
Other Names:Procedure: diffusion-weighted magnetic resonance imaging
Undergo diffusion-weighted MRI
Other Name: diffusion-weighted MRIProcedure: dynamic contrast-enhanced magnetic resonance imaging
Other Name: DCE-MRIProcedure: magnetic resonance spectroscopic imaging
Undergo MR spectroscopy
I. To assess the impact of prostate MRI, without an endorectal coil, done at 3-Tesla on surgical management. This would be performed by examining the agreement of lesion location based on the MRI compared to the lesion location based on pathology and/or surgery and local extent of the disease, i.e. involvement of contiguous organs and local lymph nodes, based on the MRI compared to the local extent based on pathology and/or surgery.
II. To test the reproducibility of functional MRI (dynamic-contrast enhanced [DCE_MRI] MRI, magnetic resonance [MR] spectroscopy and diffusion-weighted MRI).
I. To assess the usefulness of MRI data in treatment planning for radiation therapy, and to test the feasibility of amide-proton-transfer MRI in prostate cancer detection.
II. To evaluate MRI changes in prostate and tumor morphology between endorectal coil versus no endorectal coil.
III. To assess the usefulness of ex-vivo prostate specimen MRI for accurate co-registration between in-vivo MRI of the prostate and pathology slides.
Patients undergo 3-tesla (3T) MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01653093
|Contact: The Ohio State University Comprehensive Cancer Center||1-800-293-5066||Jamesline@osumc.edu|
|Contact: Michael Knopp, MDemail@example.com|
|United States, Ohio|
|The Ohio State University Medical Center, Stress||Recruiting|
|Columbus, Ohio, United States, 43210|
|Contact: Michael V. Knopp 614-293-9998 firstname.lastname@example.org|
|Principal Investigator: Michael V. Knopp|
|Principal Investigator:||Michael Knopp, MD||Ohio State University|